Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotarem-enhanced MRA vs TOF MRA in Renal Arterial Disease
NCT00980681Phase 3Terminated
- Sponsor
- Guerbet
- Start
- Sep 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gadoterate meglumine in renal artery stenosis (RAS), sponsored by Guerbet. Started Sep 2009; status: terminated.
02
Drugs
gadoterate meglumine
03
Conditions
renal artery stenosis (RAS)
Beyond the preview
Go deeper on NCT00980681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00980681.